Abstract | BACKGROUND: MATERIALS AND METHODS: RESULT: Our findings revealed a significant decrease in MPO in G2013 treated group, indicating its favorable effects but has no significant effects on genes expression of another antioxidant enzymes, including: SOD2, CAT, GPX1, and GST. Also, there were no significant differences in PCO, TAC and cortisol compared to control group following G2013 consumption. While an enhancement in serum MDA level was observed in the treatment group. In addition, G2013 therapy did not show any weight loss. CONCLUSIONS: Our data showed the safety and efficacy of G2013 as a novel designed NSAID on various oxidative stress determinants.
|
Authors | Abbas Mirshafiey, Soma Hosseini, Sanaz Afraei, Noshin Rastkari, Farzaneh Tofighi Zavareh, Gholamreza Azizi |
Journal | Current drug discovery technologies
(Curr Drug Discov Technol)
Vol. 13
Issue 1
Pg. 25-33
( 2016)
ISSN: 1875-6220 [Electronic] United Arab Emirates |
PMID | 26906909
(Publication Type: Journal Article)
|
Chemical References |
- Anti-Inflammatory Agents, Non-Steroidal
- Immunosuppressive Agents
|
Topics |
- Animals
- Anti-Inflammatory Agents, Non-Steroidal
(pharmacology)
- Immunosuppressive Agents
(pharmacology)
- Models, Animal
- Oxidative Stress
(drug effects)
- Rats
- Real-Time Polymerase Chain Reaction
|